A Phase 1 interventional study of MT-1186 in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Shionogi · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the comparative bioavailability of edaravone oral suspension administered orally and via a nasogastric tube in healthy adult subjects
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: Subjects who meet all of the following criteria and who have the capability of giving will be included in the study.
Exclusion Criteria: Subjects who meet any of the following criteria between screening and product administration will be excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive the edaravone oral suspension orally.
Drug: MT-1186
Subjects receive the edaravone oral suspension via a nasogastric tube
Drug: MT-1186
Suspension
Also known as: Edaravone
Area Under the Concentration Versus Time Curve (AUC) of Edaravone
Area under the plasma concentration versus time curve from time zero up to the last quantifiable concentration time-point (AUC0-t) of edaravone, and Area under the plasma concentration versus time curve from time zero up to infinity with extrapolation of the terminal phase (AUC0-inf) of edaravone.
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hours after administration.
Maximum Plasma Concentration (Cmax) of Edaravone
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Time to Reach Maximum Plasma Concentration (Tmax) of Edaravone
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Terminal Elimination Half-life (t1/2) of Edaravone
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Apparent Terminal Elimination Rate Constant (Kel) of Edaravone
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Mean Residence Time (MRT) of Edaravone
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Apparent Total Clearance (CL/F) of Edaravone
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Apparent Distribution Volume at Elimination Phase (Vz/F) of Edaravone
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Apparent Distribution Volume at Steady State (Vss/F) of Edaravone
Time frame: Plasma samples are collected: Day 1 and Day 4 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours; Day 2 and Day 5 at 24 and 36 hours; Day 3 and Day 6 at 48 hour after administration.
Number of Participants With Adverse Events and Adverse Drug Reactions
Time frame: Day 1 to 11
| Milestone | MT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT) | MT-1186 Via NGT, Then MT-1186 Orally |
|---|---|---|
| Started | 18 | 18 |
| Completed | 18 | 18 |
| Not completed | 0 | 0 |
| Milestone | MT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT) | MT-1186 Via NGT, Then MT-1186 Orally |
|---|---|---|
| Started | 18 | 18 |
| Completed | 18 | 18 |
| Not completed | 0 | 0 |
Area under the plasma concentration versus time curve from time zero up to the last quantifiable concentration time-point (AUC0-t) of edaravone, and Area under the plasma concentration versus time curve from time zero up to infinity with extrapolation of the terminal phase (AUC0-inf) of edaravone.
| ng·h/mL | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| AUC0-t | 2612 ± 787 | 2592 ± 866 |
| AUC0-inf | 2657 ± 801 | 2617 ± 870 |
| ng/mL | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Edaravone | 2470 ± 839.8 | 2775 ± 1444 |
| h | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Edaravone | 0.50 (0.25 to 0.50) | 0.25 (0.08 to 1.00) |
| h | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Terminal Elimination Half-life (t1/2) of Edaravone | 21.52 ± 33.83 | 13.53 ± 13.81 |
| 1/h | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Apparent Terminal Elimination Rate Constant (Kel) of Edaravone | 0.06430 ± 0.03776 | 0.07713 ± 0.03269 |
| h | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Mean Residence Time (MRT) of Edaravone | 4.66 ± 8.89 | 2.89 ± 1.44 |
| L/h | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Apparent Total Clearance (CL/F) of Edaravone | 42.8 ± 12.3 | 43.8 ± 12.6 |
| L | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Apparent Distribution Volume at Elimination Phase (Vz/F) of Edaravone | 1209 ± 1682 | 816 ± 782 |
| L | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Apparent Distribution Volume at Steady State (Vss/F) of Edaravone | 183.7 ± 299.9 | 125.4 ± 67.7 |
| Participants | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Number of Participants with Adverse events | 1 | 3 |
| Number of Participants with adverse drug reactions | 0 | 1 |
Collected over The provision of informed consent to Day 11. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MT-1186 Orally | 0/36 (0%) | 0/36 (0%) | 1/36 (2.8%) |
| MT-1186 Via NGT | 0/36 (0%) | 0/36 (0%) | 3/36 (8.3%) |
| Event | MT-1186 Orally | MT-1186 Via NGT |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/36 | 2/36 |
| Aspartate aminotransferase increasedInvestigations | 0/36 | 1/36 |
| Blood creatine phosphokinase increasedInvestigations | 0/36 | 1/36 |
| Blood creatinine increasedInvestigations | 1/36 | 0/36 |
| C-reactive protein increasedInvestigations | 0/36 | 1/36 |
| Age, Categorical(Participants) | MT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT) | MT-1186 Via NGT, Then MT-1186 Orally | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 18 | 36 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | MT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT) | MT-1186 Via NGT, Then MT-1186 Orally | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 12 | 12 | 24 |
| Race (NIH/OMB)(Participants) | MT-1186 Orally, Then MT-1186 Via a Nasogastric Tube (NGT) | MT-1186 Via NGT, Then MT-1186 Orally | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 18 | 18 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Apr 2021, 1 month.
Results were first posted in Jan 2024, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone